[1]	Weight-loss drug maker Novo Nordisk becomes Europe’s most valuable company [Internet].London: Financial Times; 2023 Sep 4 [ 2023 Sep 28]

[2]	J.P.H. Wilding, R.L. Batterham, S. Calanna, M. Davies, L.F. Van Gaal, I. Lingvay, et al.. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med, 384 (11) ( 2021), pp. 989-1002

[3]

M. Davies, L. Faerch, O. Jeppesen, A. Pakseresht, S.D. Pederson, L. Perreault, et al.. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet, 397 (10278) ( 2021), pp. 971-984

[4]	Diabetes and obesity are rising globally—but some nations are hit harder [Internet]. London: Nature; 2023 Mar 7 [ 2023 Sep 28]

[5]	Weight-loss injections have taken over the internet. But what does this mean for people IRL? [Internet]. Cambridge: MIT Technology Review; 2023 Mar 20 [ 2023 Sep 28]

[6]	Constantino AK. Eli Lilly raises full-year guidance as Mounjaro, other drugs drive second-quarter profit up 85% [Internet]. New York City:CNBC; 2023 Aug 8 [cited 2023 Oct 2].

[7]	A.M. Jastreboff, L.J. Aronne, N.N. Ahmad, S. Wharton, L. Connery, B. Alves, et al.. Tirzepatide once weekly for the treatment of obesity. N Engl J Med, 387 (3) ( 2022), pp. 205-216

[8]	Lilly’s tirzepatide achieved up to 15.7% weight loss in adults with obesity or overweight and type 2 diabetes in SURMOUNT-2 [Internet]. Indianapolis: Lilly Investors; 2023 Apr 27 [cited 2023 Sep 28].

[9]	A.M. Jastreboff, L.M. Kaplan, J.P. Frias, Q. Wu, Y. Du, S. Gurbuz, et al.. Triple-hormone-receptor agonist retatrutide for obesity—a phase 2 trial. N Engl J Med, 389 (6) ( 2023), pp. 514-526

[10]	Mullin E. A pill version of ozempic is coming [Internet]. San Francisco: Wired; 2023 Jun 1 [ 2023 Sep 28]

[11]	F.K. Knop, V.R. Aroda, R.D. do Vale, T. Holst-Hansen, P.N. Laursen, J. Rosenstock, et al.. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 402 (10403) ( 2023), pp. 705-719

[12]	Lilly links oral obesity drug to 15% weight loss, setting bar for Pfizer in blockbuster battle [Internet]. Washington, DC: Fierce Biotech; 2023 Jun 23 [cited 2023 Sep 28].

[13]	S. Wharton, T. Blevins, L. Connery, J. Rosenstock, S. Raha, R. Liu, et al..Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N Engl J Med, 389 (10) ( 2023), pp. 877-888

[14]	Lingvay I, Agarwal S.A revolution in obesity treatment [Internet]. London: Nature Medicine; 2023 Sep 21 [ 2023 Sep 28]

[15]	Amylin and Lilly announce FDA approval of BYETTA(TM) ( exenatide) injection [Internet]. Indianapolis: Lilly Investors; 2005 Apr 29 [ 2023 Sep 28]

[16]	Obesity and overweight [Internet]. Geneva: World Health Organization; 2021 Jun 9 [ 2023 Sep 28]

[17]	Semaglutide 2.4 mg reduces the risk of major adverse cardiovascular events by 20% in adults with overweight or obesity in the SELECT trial [Internet].Bagsværd: Novo Nordisk; 2023 Aug 8 [cited 2023 Sep 28].

[18]	P. Dandona, A. Chaudhuri, H. Ghanim.Semaglutide in early type 1 diabetes. N Engl J Med, 389 (10) ( 2023), pp. 958-959

[19]	Zhang S. Did scientists accidentally invent an anti-addiction drug? [Internet]. Washington, DC: The Atlantic; 2023 May 19 [ 2023 Sep 28]

[20]	Blum D. Ozempic can cause major weight loss. What happens if you stop taking it? [Internet]. New York City: New York Times; 2023 Feb 23 [ 2023 Sep 28]

[21]	Muller M.Weight-loss drugs like Ozempic and Wegovy may be risky for older people because they melt away all-important muscles, experts say [Internet]. New York City: Fortune; 2023 Sep 27 [ 2023 Sep 28]